Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754417 | 0.85 | PARP1 (0.59) | PARP1PRMT5HTR3AHTR4RXFP1 | |
| SCHEMBL1477698 | 0.83 | PARP1 (0.69) | PARP1PRMT5HTR3AHTR4RXFP1 | |
| SCHEMBL1082188 | 0.81 | EGLN1 (0.63) | PARP1PRMT5HTR3AHTR4RXFP1 | |
| SCHEMBL536589 | 0.80 | PARP1 (0.64) | PARP1 | |
| SCHEMBL29698487 | 0.80 | PARP1 (0.64) | PARP1PRMT5RXFP1 | |
| SCHEMBL26177802 | 0.79 | PARP1 (0.59) | PARP1PRMT5RXFP1 | |
| SCHEMBL30848472 | 0.78 | PARP1 (0.55) | PARP1PRMT5RXFP1 | |
| SCHEMBL1382494 | 0.78 | TSHR (0.56) | PARP1 | |
| SCHEMBL5480367 | 0.78 | PARP1 (0.66) | PARP1PRMT5RXFP1 | |
| SCHEMBL5823494 | 0.76 | PARP1 (0.59) | PARP1PRMT5RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | PARP1 1929/4885PRMT5 692/4885HTR3A 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.